Multifunctional Natural Polymer Nanoparticles as Antifibrotic Gene Carriers for CKD Therapy
- 7 August 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 31 (10), 2292-2311
- https://doi.org/10.1681/asn.2019111160
Abstract
Background Progressive fibrosis is the underlying pathophysiological process of CKD, and targeted prevention or reversal of the profibrotic cell phenotype is an important goal in developing therapeutics for CKD. Nanoparticles offer new ways to deliver antifibrotic therapies to damaged tissues and resident cells to limit manifestation of the profibrotic phenotype. Methods We focused on delivering plasmid DNA expressing bone morphogenetic protein 7 (BMP7) or hepatocyte growth factor (HGF)–NK1 (HGF/NK1) by encapsulation within chitosan nanoparticles coated with hyaluronan, to safely administer multifunctional nanoparticles containing the plasmid DNA to the kidneys for localized and sustained expression of antifibrotic factors. We characterized and evaluated nanoparticles in vitro for biocompatibility and antifibrotic function. To assess antifibrotic activity in vivo, we used noninvasive delivery to unilateral ureteral obstruction mouse models of CKD. Results Synthesis of hyaluronan-coated chitosan nanoparticles containing plasmid DNA expressing either BMP7 or NGF/NKI resulted in consistently sized nanoparticles, which—following endocytosis driven by CD44+ cells—promoted cellular growth and inhibited fibrotic gene expression in vitro. Intravenous tail injection of these nanoparticles resulted in approximately 40%–45% of gene uptake in kidneys in vivo. The nanoparticles attenuated the development of fibrosis and rescued renal function in unilateral ureteral obstruction mouse models of CKD. Gene delivery of BMP7 reversed the progression of fibrosis and regenerated tubules, whereas delivery of HGF/NK1 halted CKD progression by eliminating collagen fiber deposition. Conclusions Nanoparticle delivery of HGF/NK1 conveyed potent antifibrotic and proregenerative effects. Overall, this research provided the proof of concept on which to base future investigations for enhanced targeting and transfection of therapeutic genes to kidney tissues, and an avenue toward treatment of CKD.Keywords
Funding Information
- Natural Science Foundation of China (81850410552)
- NSFC (81830060)
- NSFC (81701840)
- State Key Laboratory of Kidney Diseases (KF-2018-10)
- National Key Research and Development Program of China (2016YFA0101002)
This publication has 72 references indexed in Scilit:
- Chronic kidney disease: global dimension and perspectivesThe Lancet, 2013
- Mechanisms of fibrosis: therapeutic translation for fibrotic diseaseNature Medicine, 2012
- Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membraneProceedings of the National Academy of Sciences of the United States of America, 2012
- Analysis of CD44-Hyaluronan Interactions in an Artificial Membrane System: INSIGHTS INTO THE DISTINCT BINDING PROPERTIES OF HIGH AND LOW MOLECULAR WEIGHT HYALURONAN*Online Journal of Public Health Informatics, 2010
- Hepatocyte growth factor signaling ameliorates podocyte injury and proteinuriaKidney International, 2010
- Modulation of TGFβ1-Dependent Myofibroblast Differentiation by HyaluronanThe American Journal of Pathology, 2009
- Hyaluronan Orchestrates Transforming Growth Factor-β1-dependent Maintenance of Myofibroblast PhenotypeOnline Journal of Public Health Informatics, 2009
- Glomerular Endothelial Cells Form Diaphragms during Development and Pathologic ConditionsJournal of the American Society of Nephrology, 2008
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002